Are health technology assessments of pharmacogenetic tests feasible? A case study of CYP2D6 testing in the treatment of breast cancer with tamoxifen
| dc.contributor.author | Fleeman, N. | spa |
| dc.contributor.author | Payne, K. | spa |
| dc.contributor.author | Newman, W. G. | spa |
| dc.contributor.author | Howell, S. J. | spa |
| dc.contributor.author | Boland, A. | spa |
| dc.contributor.author | Oyee, J. | spa |
| dc.contributor.author | Martín Saborido, Carlos | spa |
| dc.contributor.author | Fernández Santander, Ana | |
| dc.contributor.author | Dickson, R. | spa |
| dc.date.accessioned | 2014-03-18T10:09:13Z | |
| dc.date.available | 2014-03-18T10:09:13Z | |
| dc.date.issued | 2013 | spa |
| dc.description.impact | 1.132 JCR (2013) Q4, 196/254 Pharmacology & pharmacy | spa |
| dc.identifier.citation | Fleeman, N., Payne, K., Newman, W. G., Howell, S. J., Boland, A., Oyee, J., ..., & Dickson, R. (2013). Are health technology assessments of pharmacogenetic tests feasible? A case study of CYP2D6 testing in the treatment of breast cancer with tamoxifen. Personalized Medicine, 10(6), 601-611. | spa |
| dc.identifier.doi | 10.2217/pme.13.60 | spa |
| dc.identifier.uri | http://hdl.handle.net/11268/2129 | |
| dc.language.iso | eng | spa |
| dc.peerreviewed | Si | spa |
| dc.rights.accessRights | restricted access | en |
| dc.subject.unesco | Cáncer | spa |
| dc.subject.unesco | Tratamiento médico | spa |
| dc.title | Are health technology assessments of pharmacogenetic tests feasible? A case study of CYP2D6 testing in the treatment of breast cancer with tamoxifen | spa |
| dc.type | journal article | spa |
| dspace.entity.type | Publication | |
| relation.isAuthorOfPublication | 8f0ff816-e791-403f-901d-e479575cf9e8 | |
| relation.isAuthorOfPublication.latestForDiscovery | 8f0ff816-e791-403f-901d-e479575cf9e8 |